Institut Curie

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Institut Curie

Jul 7, 2024, 06:54 | Insight

Olivier Saulnier: Cellular origins of medulloblastoma

Olivier Saulnier, Junior Group Leader at Institut Curie, made the following post on X: "Excited…

Jun 28, 2024, 05:37 | Blog

Istvan Petak: Pleasure to give a talk at the Drug Development Course 2024

Istvan Petak shared on LinkedIn: “Hello, amazing Switzerland, beautiful Bellinzona. It was a pleasure to…

May 24, 2024, 14:50 | Insight

A new paper on VC-resist glioblastoma cell state out in Nature Communications

A groundbreaking new open-access paper was published in the prestigious journal, Nature Communications, titled "VC-resist…

May 24, 2024, 13:07 | Blog

France needs to accelerate its fight against cancer! - European Cancer Organisation

European Cancer Organisation shared a post on LinkedIn: “France needs to accelerate its fight against…

Apr 11, 2024, 17:17 | Insight

Michael Duruisseaux: Practical guidance for sotorasib-related adverse events prevention and hepatotoxicity management

Michael Duruisseaux, Medical Director of the Joint Research Unit in Thoracic Oncology of the Hospices…

Mar 14, 2024, 19:28 | Drugs

François-Clément Bidard: A prospective study to document the efficacy of the combo Fulvestrant+Everolimus

Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, shared…

Jul 16, 2023, 06:48 | Stories

Therapy Resistance and Metabolic reprogramming in ER+ breast cancer: what a combo - Andrea Morandi

📣 It's OUT! Therapy Resistance and Metabolic reprogramming in ER+ breast cancer: what a combo!…

All: 7 Posts: 1 - 100